OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kris on Atezolizumab in NSCLC

November 10th 2022

Mark G. Kris, MD, discusses the role of atezolizumab in patients with non–small cell lung cancer.

Dr. Rugo on HER2 Differentiation in Metastatic Breast Cancer

November 9th 2022

Hope Rugo, MD, discusses the challenges of differentiating between HER2-low and HER2-negative metastatic breast cancer and prognostic differences in HER2+ and HER2-low metastatic breast cancer.

Dr. Klempner on the Significance of KRYSTAL-1 Data in KRAS G12C–Mutant CRC

November 9th 2022

Sam Klempner, MD, discusses the incidence of KRAS G12C mutations in patients with metastatic colorectal cancer, the viability of the target in this disease, the efficacy of adagrasib in combination with cetuximab in this patient population, and the importance of genetic testing.

Dr. Awan on Selecting BTK Inhibitors for CLL Management

November 7th 2022

Farrukh Awan, MD, discusses the current use of BTK inhibitors in the management of chronic lymphocytic leukemia and important factors to consider when determining the best treatment strategy.

Dr. Shroff on the Utility of the HIMALAYA Regimen in HCC

November 7th 2022

Rachna T. Shroff, MD, MS, discusses the utility of combining anti–CTLA-4 and anti–PD-1 therapies in hepatocellular carcinoma.

Dr. Ramakrishnan on Advancements With CAR T-cell Therapies in LBCL

November 4th 2022

Praveen Ramakrishnan, MD, MS, discusses the clinical implications of CAR T-cell therapy in large B-cell lymphoma.

Dr. McKay on Tivozanib Plus Nivolumab in Advanced RCC

November 4th 2022

Rana R. McKay, MD, discusses the rationale for combining tivozanib with nivolumab in heavily pretreated patients with renal cell carcinoma.

Dr. McGregor on Belzutifan Plus Lenvatinib in Advanced RCC

November 4th 2022

Bradley McGregor, MD, discusses the rationale behind combining belzutifan with lenvatinib in pretreated patients with advanced renal cell carcinoma with clear cell components.

Dr. Jonasch on the Exploration of Cabozantinib in the Neoadjuvant Setting in RCC

November 4th 2022

Eric Jonasch, MD, discusses the exploration of cabozantinib in the neoadjuvant setting in renal cell carcinoma.

Dr. Maron on the Role of PD-1 Inhibition in Esophagogastric Cancer

November 4th 2022

Steven Maron, MD, MSc, discusses the role of PD-1 inhibition in esophagogastric cancer.

Dr. Epstein-Peterson on the Importance of Treatment Sequencing Decisions in MCL

November 4th 2022

Zachary Epstein-Peterson, MD, discusses the importance of treatment sequencing decisions in mantle cell lymphoma.

Dr. Hahn on the Investigation of Lenvatinib/Everolimus Vs Cabozantinib in mRCC

November 4th 2022

Andrew W. Hahn, MD, discusses the investigation of lenvatinib plus everolimus vs cabozantinib in metastatic renal cell carcinoma following progression on an immune checkpoint inhibitor.

Dr. Gupta on Unmet Needs in Frontline Treatment of Metastatic Urothelial Cancer.

November 4th 2022

Shilpa Gupta, MD, discusses the unmet needs of patients with cisplatin-ineligible metastatic urothelial carcinoma.

Dr. McKay on Recent Advancements in the Frontline Treatment of Metastatic RCC

November 4th 2022

Rana R. McKay, MD, discusses four key trials that have advanced the frontline treatment of metastatic renal cell carcinoma in the modern era.

Dr. Abou-Alfa on Areas Ripe for Further Exploration in HCC

November 3rd 2022

Ghassan K. Abou-Alfa, MD, discusses areas ripe for further exploration in hepatocellular carcinoma.

Dr. Miron on Resistance Mechanisms to FGFR Inhibitors in Cholangiocarcinoma

November 3rd 2022

Benjamin Miron, MD, discusses mechanisms of resistance to FGFR inhibitors in cholangiocarcinoma.

Dr. Barzi on the Need for More Sensitive MRD Testing in CRC

November 3rd 2022

Afsaneh Barzi, MD, PhD, discusses the need for more sensitive minimal residual disease testing in colorectal cancer.

Dr. Pecora on Key Efficacy Findings from the DREAMSEQ Trial in BRAF-Mutated Melanoma

November 3rd 2022

Andrew L. Pecora, MD, discusses the key efficacy findings from the phase 3 DREAMSEQ trial in BRAF-mutated melanoma.

Dr. Piotrowska on the Management of Paronychia Associated With EGFR TKIs

November 3rd 2022

Zofia Piotrowska, MD, discusses the management of paronychia associated with EGFR TKIs.

Dr. Ramakrishnan on Negative Results of the BELINDA Trial in Non-Hodgkin Lymphoma

November 3rd 2022

Praveen Ramakrishnan, MD, discusses the negative results from the phase 3 BELINDA trial and its effect on the use of CAR T-cell products in aggressive B-cell non-Hodgkin lymphoma.